Download PDF
Planta Med 2013; 79(18): 1715-1719
DOI: 10.1055/s-0033-1351017
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Epigallocatechin-3-Gallate Inhibits Homocysteine-Induced Apoptosis of Endothelial Cells by Demethylation of the DDAH2 Gene

Bi-Kui Zhang
1   Department of Pharmaceutics, The Third Xiangya Hospital, Central South University, Changsha, China
,
Yong-Quan Lai
1   Department of Pharmaceutics, The Third Xiangya Hospital, Central South University, Changsha, China
,
Pan-Pan Niu
1   Department of Pharmaceutics, The Third Xiangya Hospital, Central South University, Changsha, China
,
Ming Zhao
2   Hunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, China
,
Su-Jie Jia
1   Department of Pharmaceutics, The Third Xiangya Hospital, Central South University, Changsha, China
2   Hunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, China
› Author Affiliations
Further Information

Publication History

received 16 May 2013
revised 25 September 2013

accepted 06 October 2013

Publication Date:
15 November 2013 (online)

    Permissions and Reprints

Abstract

Our previous study showed that hypermethylation of dimethylarginine dimethylaminohydrolase 2 contributes to homocysteine-induced apoptosis of human umbilical vein endothelial cells. Epigallocatechin-3-gallate is a green tea-derived phenol which has been proved beneficial on atherosclerosis. It was demonstrated that epigallocatechin-3-gallate inhibits DNA methyltransferase activity and reactivates methylation-silenced genes in cancer cells. The aim of this study was to address whether epigallocatechin-3-gallate could induce DNA demethylation of the dimethylarginine dimethylaminohydrolase 2 gene, contributing to prevent endothelial cells from apoptosis induced by homocysteine. Human umbilical vein endothelial cells (ATCC, CRL-2480) were treated with homocysteine (1 mM) for 48 hours with or without epigallocatechin-3-gallate (20 µM) or 5-Aza (DNA methyltransferase inhibitor, 5 µM). Apoptosis rate of human umbilical vein endothelial cells was assayed by flow cytometry with an annexin V-FITC apoptosis detection kit. The mRNA and protein expression level of dimethylarginine dimethylaminohydrolase 2 and DNA methyltransferase 1 were detected by real-time PCR and Western blot, respectively. DNA methylation level of dimethylarginine dimethylaminohydrolase 2 was assayed by methylation specific PCR. The binding level of DNA methyltransferase 1 in the promoter of dimethylarginine dimethylaminohydrolase 2 was determined by chromatin immunoprecipitation-quantitative real-time PCR. It was shown that the apoptosis rate was decreased significantly in human umbilical vein endothelial cells treated with homocysteine compared with the control. Furthermore, the mRNA and protein level of dimethylarginine dimethylaminohydrolase 2 were downregulated, the dimethylarginine dimethylaminohydrolase 2 gene promoter was hypermethylated, and the DNA methyltransferase 1 mRNA and protein level were increased in human umbilical vein endothelial cells treated with homocysteine. Chromatin immunoprecipitation-quantitative real-time PCR revealed that homocysteine-induced binding of DNA methyltransferase 1 to the dimethylarginine dimethylaminohydrolase 2 promoter was increased. Pretreatment with epigallocatechin-3-gallate or 5-Aza inhibited such effects of homocysteine. In conclusion, epigallocatechin-3-gallate exerted protective effects on homocysteine-induced apoptosis in human umbilical vein endothelial cells by inhibiting promoter hypermethylation of the dimethylarginine dimethylaminohydrolase 2 gene and inducing dimethylarginine dimethylaminohydrolase 2 expression. These effects may be due to the decreased DNA methyltransferase 1 expression and binding of DNA methyltransferase 1 to the dimethylarginine dimethylaminohydrolase 2 promoter induced by epigallocatechin-3-gallate. This research suggests that modulating the epigenetic processes might be a novel plausible way for treatment of atherosclerosis.

Key words

epigallocatechin-3-gallate - DNA methylation - DDAH2 - endothelial cells - apoptosis
 

  • References

  • 1 Galleano M, Pechanova O, Fraga CG. Hypertension, nitric oxide, oxidants, and dietary plant polyphenols. Curr Pharm Biotechnol 2010; 11: 837-848
    CrossrefPubMedGoogle Scholar
  • 2 Moore RJ, Jackson KG, Minihane AM. Green tea (Camellia sinensis) catechins and vascular function. Br J Nutr 2009; 102: 1790-1802
    CrossrefPubMedGoogle Scholar
  • 3 Baccarelli A, Ghosh S. Environmental exposures, epigenetics and cardiovascular disease. Curr Opin Clin Nutr Metab Care 2012; 15: 323-329
    CrossrefPubMedGoogle Scholar
  • 4 Zaina S, Lund G. Epigenetics: a tool to understand diet-related cardiovascular risk?. J Nutrigenet Nutrigenomics 2011; 4: 261-274
    CrossrefPubMedGoogle Scholar
  • 5 Webster AL, Yan MS, Marsden PA. Epigenetics and cardiovascular disease. Can J Cardiol 2013; 29: 46-57
    CrossrefPubMedGoogle Scholar
  • 6 Marin M, Manez S. Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease. Curr Med Chem 2011; 18: 714-724
    CrossrefPubMedGoogle Scholar
  • 7 Tang WJ, Hu CP, Chen MF, Deng PY, Li YJ. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level. Can J Physiol Pharmacol 2006; 84: 163-171
    CrossrefPubMedGoogle Scholar
  • 8 Jia SJ, Lai YQ, Zhao M, Gong T, Zhang BK. Homocysteine-induced hypermethylation of DDAH2 promoter contributes to apoptosis of endothelial cells. Pharmazie 2013; 68: 282-286
    PubMedGoogle Scholar
  • 9 Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-7570
    PubMedGoogle Scholar
  • 10 Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem 2010; 17: 2141-2151
    CrossrefPubMedGoogle Scholar
  • 11 Deka A, Vita JA. Tea and cardiovascular disease. Pharmacol Res 2011; 64: 136-145
    CrossrefPubMedGoogle Scholar
  • 12 Thaler R, Agsten M, Spitzer S, Paschalis EP, Karlic H, Klaushofer K, Varga F. Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. J Biol Chem 2011; 286: 5578-5588
    CrossrefPubMedGoogle Scholar
  • 13 Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomaki S, Airenne K, Janne J, Yla-Herttuala S. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol 1999; 19: 2171-2178
    CrossrefPubMedGoogle Scholar
  • 14 Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, Heimburger O, Barany P, Alvestrand A, Nordfors L, Qureshi AR, Ekstrom TJ, Schalling M. Impact of inflammation on epigenetic DNA methylation – a novel risk factor for cardiovascular disease?. J Intern Med 2007; 261: 488-499
    CrossrefPubMedGoogle Scholar
  • 15 Sharma P, Kumar J, Garg G, Kumar A, Patowary A, Karthikeyan G, Ramakrishnan L, Brahmachari V, Sengupta S. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol 2008; 27: 357-365
    CrossrefPubMedGoogle Scholar
  • 16 Zhang D, Xie X, Chen Y, Hammock BD, Kong W, Zhu Y. Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo . Circ Res 2012; 110: 808-817
    CrossrefPubMedGoogle Scholar